Articles

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

Division of Hematology, Stanford University School of Medicine, Stanford, USA
Department of Veterans Affairs VA Palo Alto Health Care System, Palo Alto, USA
Division of Hematology, Stanford University School of Medicine, Stanford, USA
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, USA
Division of Bone Marrow Transplantation, Stanford University School of Medicine, Stanford, USA
Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA
Division of Hematology, Stanford University School of Medicine, Stanford, USA
Division of Hematology, Stanford University School of Medicine, Stanford, USA
Vol. 98 No. 10 (2013): October, 2013 https://doi.org/10.3324/haematol.2013.084574